1. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. (3rd May 2016) Authors: Noda, Shoko; Kanda, Shintaro Journal: Expert review of respiratory medicine Issue: Volume 10:Number 5(2016) Page Start: 547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody. Issue 12 (27th October 2020) Authors: Murakami, Shuji; Shibaki, Ryota; Matsumoto, Yuji; Yoshida, Tatsuya; Goto, Yasushi; Kanda, Shintaro; Horinouchi, Hidehito; Fujiwara, Yutaka; Yamamoto, Noboru; Ohe, Yuichiro Journal: Thoracic cancer Issue: Volume 11:Issue 12(2020) Page Start: 3585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy. Issue 7 (13th February 2022) Authors: Araki, Taisuke; Tateishi, Kazunari; Komatsu, Masamichi; Sonehara, Kei; Kanda, Shintaro; Hanaoka, Masayuki; Koizumi, Tomonobu Journal: Thoracic cancer Issue: Volume 13:Issue 7(2022) Page Start: 1006 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. (October 2018) Authors: Sekine, Katsutoshi; Kanda, Shintaro; Goto, Yasushi; Horinouchi, Hidehito; Fujiwara, Yutaka; Yamamoto, Noboru; Motoi, Noriko; Ohe, Yuichiro Journal: Lung cancer Issue: Volume 124(2018) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab. Issue 5 (12th January 2021) Authors: Araki, Taisuke; Tateishi, Kazunari; Sonehara, Kei; Hirota, Shuko; Komatsu, Masamichi; Yamamoto, Manabu; Kanda, Shintaro; Kuraishi, Hiroshi; Hanaoka, Masayuki; Koizumi, Tomonobu Journal: Thoracic cancer Issue: Volume 12:Issue 5(2021) Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparative analysis of PET findings and clinical outcome in patients with primary mediastinal seminoma. Issue 3 (24th July 2013) Authors: Koizumi, Tomonobu; Katou, Akane; Ikegawa, Kayoko; Kosaka, Mitsuru; Tateishi, Kazunari; Yokoyama, Toshiki; Ushiki, Atsuto; Kanda, Shintaro; Tsushima, Kenji; Yamamoto, Hiroshi; Hanaoka, Masayuki; Kubo, Keishi; Yoshida, Kazuo; Oguchi, Kazuhiko Journal: Thoracic cancer Issue: Volume 4:Issue 3(2013) Page Start: 241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Issue 3 (September 2015) Authors: Kanda, Shintaro; Horinouchi, Hidehito; Fujiwara, Yutaka; Nokihara, Hiroshi; Yamamoto, Noboru; Sekine, Ikuo; Kunitoh, Hideo; Kubota, Kaoru; Tamura, Tomohide; Ohe, Yuichiro Journal: Lung cancer Issue: Volume 89:Issue 3(2015:Sep.) Page Start: 287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021) Authors: Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer. Issue 5 (26th March 2019) Authors: Tamura, Nobumasa; Horinouchi, Hidehito; Sekine, Katsutoshi; Matsumoto, Yuji; Murakami, Shuji; Goto, Yasushi; Kanda, Shintaro; Fujiwara, Yutaka; Yamamoto, Noboru; Ohe, Yuichiro Journal: Thoracic cancer Issue: Volume 10:Issue 5(2019) Page Start: 1141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗